Cisplatin liposomal - Regulon

Drug Profile

Cisplatin liposomal - Regulon

Alternative Names: Lipoplatin; Nanoplatin for NSCLC - Regulon

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regulon
  • Developer Centre Hospitalier Universitaire Vaudois; Regulon
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II/III Pancreatic cancer
  • Phase II Breast cancer; Gastric cancer
  • Phase I Malignant pleural effusion
  • No development reported Bladder cancer; Glioblastoma; Head and neck cancer; Ovarian cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Glioblastoma in Greece (IV, Infusion)
  • 01 Nov 2016 Regulon suspends phase II/III trial in Pancreatic cancer in Greece (EudraCT2006-005485-40)
  • 03 Sep 2016 Adverse events and efficacy data from a phase II trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top